Impact of passing mesenchymal stem cells through smaller bore size needles for subsequent use in patients for clinical or cosmetic indications

Table 1 Viability and phenotype of BM-MSCs ejected via 26 G bore size needle for multiple times

	Control	2^nd Jab	4^th Jab	6^th Jab	8^th Jab	10^th Jab
Viability	98.25% ± 1.45	96.98% ± 2.11	97.38% ± 2.23	95.89% ± 1.89	96.18% ± 2.19	97.35% ± 1.95
CD44	98.68% ± 1.42	98.89% ± 1.18	98.13% ± 1.56	98.54% ± 1.39	98.72% ± 1.28	98.31% ± 1.49
CD73	98.97% ± 1.16	98.63% ± 1.36	98.48% ± 1.41	98.77% ± 1.29	98.22% ± 1.67	98.41% ± 1.37
CD166	96.48% ± 2.24	97.12% ± 2.16	96.29% ± 2.31	97.71% ± 2.24	97.11% ± 2.18	96.89% ± 2.29
CD34	0.02%	0.23%	0.76%	0.94%	0.68%	0.85%
CD45	0.06%	0.66%	0.47%	0.57%	0.81%	0.90%
HLA-DR	0.05%	0.11%	0.76%	0.84%	0.93%	0.18%

ISSN: 1479-5876